ResMed (NYSE: RMD) reported Q1 EPS of $1.51, in-line with the analyst estimate of $1.51. Revenue for the quarter came in at $950.3 million versus the consensus estimate of $947.96 million.

For earnings history and earnings-related data on ResMed (RMD) click here.